approxim
million
case
death
report
malaria
remain
import
human
parasit
diseas
among
five
plasmodium
speci
abl
infect
human
p
falciparum
respons
case
sever
diseas
death
mainli
african
children
age
five
morbid
caus
p
vivax
tropic
countri
outsid
africa
long
underestim
anstey
et
al
baird
malaria
factor
poverti
endem
countri
stratton
et
al
absenc
effect
vaccin
reliabl
approach
vector
control
chemotherapi
remain
corner
stone
malaria
control
quinin
first
wide
use
antimalari
drug
synthet
deriv
quinin
primaquin
chloroquin
cq
resist
cq
emerg
late
strategi
modifi
chemic
structur
exist
compound
synthesi
cqlike
drug
led
discoveri
amodiaquin
aq
later
mefloquin
mq
halofantrin
unit
state
lumefantrin
china
baird
pace
new
drug
develop
slow
new
antimalari
drug
introduc
clinic
practic
sinc
artemetherlumefantrin
regist
olliaro
well
new
antimalari
drug
introduc
risk
resist
reduc
combin
therapi
white
nosten
white
guidelin
recommend
new
treatment
combin
two
drug
differ
mechan
action
treatment
contain
artemisinin
deriv
artemisinincombin
therapi
act
standard
treatment
falciparum
malaria
howev
declin
suscept
artesun
recent
report
thai
cambodian
border
region
dondorp
et
al
search
new
molecul
antimalari
activ
import
ever
mani
strategi
use
search
afford
effici
antimalari
drug
strategi
includ
ethnopharmacolog
ie
bioevalu
effici
tradit
medicin
medicin
chemistri
combinatori
chemistri
chemic
librari
screen
high
throughput
screen
drug
design
strategi
led
discoveri
potenti
antimalari
synthet
endoperoxid
other
dhanawat
et
al
clinic
develop
new
compound
often
stop
variou
reason
toxic
chemistri
pharmacolog
econom
less
one
ten
promis
molecul
enter
pipelin
reach
stage
clinic
studi
mid
extend
strategi
develop
jaouen
vessier
et
al
anticanc
therapi
antimalari
therapi
see
chavain
biot
review
main
antimalari
current
use
cq
quinin
mefloquin
artemisinin
atovaquon
modifi
introduct
ferrocenyl
moieti
chemic
structur
ferrocen
analogu
synthes
us
other
biot
dive
ferrocen
analogu
systemat
test
vitro
cultur
p
falciparum
cqsuscept
cqresist
strain
ferroquin
fq
rapidli
identifi
lead
compound
meet
candid
nomin
requir
biot
et
al
clinic
phase
iib
studi
efficacysafeti
adult
adolesc
children
began
africa
minireview
focu
discoveri
fq
antimalari
activ
hypothesi
mode
action
recent
clinic
trial
sinc
other
systemat
prepar
organometal
version
antimalari
current
use
cq
primaquin
mepacrin
mefloquin
quinin
artemisinin
atovaquon
see
dive
biot
review
new
sandwich
halfsandwich
metal
complex
dunitz
et
al
synthes
character
vitro
test
antimalari
activ
perform
organometal
compound
priori
unknown
antimalari
activ
still
screen
collect
almost
compound
made
avail
among
organometallicdrug
hybrid
interest
compound
ferrocenedrug
hybrid
among
ferrocenechloroquin
hybrid
promiss
fig
note
ferroceneartemisiten
hybrid
show
also
interest
properti
activ
equal
artemisinin
delha
et
al
dive
biot
ferrocenecq
hybrid
seri
shown
ferrocen
moieti
coval
flank
alkylamin
biot
et
al
ferroquin
fq
first
compound
synthes
us
biot
et
al
later
second
gener
analogu
fq
design
investig
exampl
synthes
dual
molecul
includ
fq
analogu
conjug
glutathion
reductas
inhibitor
glutathion
depletori
chavain
et
al
nevertheless
strategi
fail
identifi
new
lead
develop
interestingli
aminoalcohol
base
fq
structur
activ
cqsuscept
cq
cqresist
cqr
clone
p
falciparum
addit
second
gener
analogu
ferrocen
aminoalcohol
exert
antivir
effect
select
toward
sarscov
infect
biot
et
al
fq
antimalari
activ
compar
cq
standard
vitro
parasit
growth
inhibit
method
base
tritiat
hypoxanthin
incorpor
erythrocyt
infect
p
falciparum
incub
hour
desjardin
et
al
preliminari
studi
shown
fq
equal
activ
base
ditartr
dichlorhydr
salt
unpublish
result
test
result
avail
studi
perform
differ
laboratori
use
cq
cqr
p
falciparum
laboratori
adapt
clone
repres
fig
result
show
respons
cq
easili
dissoci
suscept
resist
clone
spread
respect
either
side
nm
cq
howev
fq
equal
activ
type
clone
least
equal
activ
often
activ
cq
cq
parasit
resist
fq
occur
cqr
clone
correl
found
suscept
fq
polymorph
transport
protein
implic
quinolin
resist
henri
et
al
antimalari
activ
fq
test
variou
rodent
malaria
strain
p
berghei
p
yoelii
p
vinckei
standard
four
day
test
peter
adapt
determin
cur
dose
p
berghei
n
p
yoelii
ns
strain
fq
cq
close
treatment
decreas
parasitaemia
end
assay
simpl
four
day
test
could
lead
conclud
better
efficaci
fq
versu
cq
cur
test
signific
show
p
berghei
p
vinckei
infect
cure
presenc
mgkgd
fq
four
day
cq
mgkgd
necessari
cure
cq
strain
drug
unabl
cure
resist
strain
even
toxic
dose
biot
et
al
delha
et
al
dive
biot
biot
dive
moreov
shown
fq
activ
subcutan
administr
also
oral
rout
interest
indic
concern
bioavail
drug
digest
tract
confirm
addit
pharmacokinet
studi
biot
dive
fq
racem
compound
two
stereoisom
synthet
show
antimalari
activ
similar
parent
compound
vitro
delha
et
al
first
postul
metabol
fq
may
share
common
pathway
cq
potenti
metabolit
nmonodemethylfq
ndidemethyl
fq
synthes
test
biot
et
al
metabol
fq
studi
detail
vitro
enabl
determin
degrad
pathway
daher
et
al
vitro
fq
mainli
metabol
major
nmonodemethyl
metabolit
potenti
metabolit
ndidemethyl
compound
antimalari
activ
nmonodemethylfq
found
compar
parent
compound
two
cq
clone
remain
much
activ
cq
two
cqr
clone
anoth
hand
ndidemethylfq
decreas
activ
cqr
clone
mainli
compound
taken
account
daher
et
al
compound
evalu
standard
vitro
parasit
growth
inhibit
method
erythrocyt
infect
p
falciparum
incub
least
hour
drug
antimalari
activ
fq
blood
clinic
isol
cq
cqr
multidrug
resist
isol
infect
p
falciparum
assess
seven
differ
studi
african
patient
seneg
gabon
pradin
et
al
attek
et
al
kreidenweiss
et
al
southeast
asian
patient
chim
et
al
barend
et
al
comparison
exist
antimalari
drug
data
fq
cq
artesun
report
tabl
take
studi
togeth
fq
evalu
clinic
isol
southeast
asia
africa
studi
fq
like
artesun
display
potent
antimalari
activ
p
falciparum
rang
nm
ngml
fq
nm
ngml
artesun
equal
efficaci
upon
cq
cqr
clinic
isol
resist
isol
nm
repres
sampl
addit
studi
thailand
main
fq
vivo
metabolit
investig
barend
et
al
shown
highli
potent
p
falciparum
n
nm
confid
interv
ci
nm
ngml
ci
ngml
clinic
isol
investig
whether
p
vivax
sensit
fq
studi
conduct
northwestern
thailand
isol
collect
octob
april
examin
effect
fq
demethyl
metabolit
ring
stage
schizont
matur
microscopi
sampl
collect
patient
acut
p
vivax
monospeci
parasitaemia
white
blood
cell
fq
found
potent
ex
vivo
effect
p
vivax
schizont
matur
median
nm
ci
nm
n
less
activ
nm
ci
nm
signific
crosssensit
fq
antimalari
detect
consequ
fq
may
suitabl
replac
chloroquin
treatment
drugresist
p
vivax
malaria
leimani
et
al
gabones
studi
kreidenweiss
et
al
report
comparison
kreidenweiss
et
al
artesun
fq
nm
ci
nm
ngml
ci
ngml
nm
ci
nm
ngml
ci
ngml
valu
close
report
indic
strong
potenc
abil
effici
kill
parasit
present
field
isol
final
suscept
p
falciparum
isol
madagascar
n
guyana
n
cambodia
n
fq
measur
local
pasteur
institut
use
hypoxanthin
incorpor
method
mean
minimum
maximum
valu
nm
nm
nm
respect
eric
legrand
person
commun
studi
crossresist
observ
cq
antimalari
although
weak
occurr
could
attribut
one
studi
fluctuat
initi
inoculum
use
test
kreidenweiss
et
al
absenc
crossresist
support
molecular
studi
show
associ
polymorphim
resist
pfcrt
gene
main
molecular
marker
cq
fq
suscept
field
isol
daher
et
al
last
observ
extend
marker
quinolin
resist
henri
et
al
pymdr
pycrt
gene
rodent
strain
p
yoelii
dive
biot
vitro
studi
p
falciparum
resist
acquisit
ferroquin
pressur
perform
human
red
blood
cell
infect
clone
two
month
fq
pressur
unabl
obtain
viabl
resist
strain
experi
howev
observ
parasit
unabl
develop
transfer
drugfre
medium
daher
et
al
attempt
obtain
rodent
fqr
strain
start
p
yoelii
result
phenotyp
fix
genet
resist
disappear
soon
fq
pressur
remov
moreov
phenotyp
emerg
slowli
confin
strictli
reticulocyt
easili
clear
host
dive
biot
result
clearli
show
fit
cost
fq
resist
high
parasit
would
detriment
competit
nonresist
clone
cq
thought
act
interf
digest
haemoglobin
blood
stage
malaria
life
cycl
even
cq
fq
share
similar
activ
fq
clearli
show
import
addit
mechan
action
compar
cq
tabl
ii
biot
et
al
dubar
et
al
weaker
base
properti
fq
compar
cq
combin
higher
lipophil
ph
peculiar
conform
provid
intramolecular
hydrogen
bond
present
non
polar
condit
result
better
potenc
fq
cross
membran
higher
accumul
digest
vacuol
ph
organel
physicochem
properti
fq
evidenc
higher
fraction
neutral
monoproton
form
suggest
effici
inhibitori
activ
hematin
biocrystal
dubar
et
al
verifi
vitro
bhia
inhibit
assay
moreov
preferenti
local
fq
site
crystal
hemozoin
close
membran
acid
vacuol
might
induc
two
independ
concomit
behaviour
first
fq
might
inhibit
self
assembl
hemozoin
crystal
second
fq
might
specif
gener
reactiv
oxygen
speci
per
se
via
destruct
hemozoin
crystal
induc
lipid
peroxid
alter
digest
vacuol
chavain
et
al
dubar
et
al
properti
might
explain
fq
activ
cq
vitro
even
suscept
p
falciparum
clone
vitro
assay
emphas
specif
import
intramolecular
hydrogen
bond
fq
inde
studi
base
methyl
fq
analogu
fq
without
intramolecular
hydrogen
bond
due
presenc
methyl
group
group
clearli
show
presenc
intramolecular
hydrogen
bond
allow
fq
escap
resist
mechan
avoid
crossresist
current
antimalari
biot
et
al
dubar
et
al
total
subject
patient
administ
fq
june
seven
complet
phase
studi
male
subjectspati
part
two
trial
perform
healthi
caucasian
subject
four
trial
conduct
asymptomat
african
patient
infect
p
falciparum
one
phase
iia
doseescal
safeti
activ
includ
adult
african
patient
monoinfect
p
falciparum
parasitemia
within
limit
ongo
phase
iib
doserang
studi
account
patient
conduct
across
seven
african
countri
current
assess
four
group
safeti
efficaci
associ
fqat
three
dose
level
artesun
fq
alon
patient
mono
infect
p
falciparum
first
second
cohort
consist
adultadolesc
patient
children
kg
complet
potenti
combin
indic
evalu
time
write
review
conclus
fq
clinic
trial
enabl
definit
condit
use
new
antimalari
drug
appear
well
posit
pipelin
one
remain
question
caus
potent
activ
drug
mainli
toward
cq
resist
parasit
relat
structur
molecul
clue
role
hydrogen
bond
role
redox
activ
natur
metal
present
metallocen
moieti
current
examin
clarifi
mechan
entri
fq
infect
red
blood
cell
site
mechan
action
relat
transport
involv
resist
differ
aminoquinolin
appear
ineffect
expel
molecul
parasit
clinic
front
remain
determin
new
drug
best
combin
partner
limit
risk
resist
